AI 面板
AI智能体对这条新闻的看法
Despite a modest increase in institutional holdings, the panel is cautious about AbbVie's future due to the looming Humira patent cliff, integration risks from recent acquisitions, and potential capital structure issues. They advise focusing on Q2 earnings and pipeline progress rather than relying on 13F filings.
风险: Integration delays or failures of recent acquisitions (ImmunoGen and Cerevel) could spike the interest coverage ratio below 3x, pressuring the balance sheet and potentially capping multiple expansion.
机会: Successful integration and growth of the Skyrizi and Rinvoq pipelines could offset the Humira patent cliff and drive long-term EPS growth.
完整文章
Nasdaq
在 Holdings Channel，我们已经审查了最近 51 份 13F 申报中的最新一批，报告期为 2026 年 3 月 31 日，注意到 AbbVie Inc（代码：ABBV）被其中 34 支基金持有。当对冲基金经理似乎在思考相同的问题时，我们认为仔细研究一下是个好主意。
在我们继续之前，重要的是要指出 13F 申报并不完整，因为这些基金只需要向美国证券交易委员会披露其 *长* 头寸，但不需要披露其 *短* 头寸。例如，一家基金通过做空看跌期权对一家股票进行看跌押注，也可能在其整体看跌头寸周围进行交易时持有一定数量的股票。这种长头寸可能会出现在 13F 申报中，每个人都可能认为该基金看涨，但这只告诉了故事的一部分 *因为该头寸的看跌/做空方面没有被看到*。
考虑到这一警告，我们认为查看 13F 申报的 *群体* 可以揭示一些信息，尤其是在将一个持有期间与另一个持有期间进行比较时。下面，让我们看看这份最新 13F 申报者对 ABBV 头寸的变化：
在持股数量方面，我们发现上述 14 支基金在 2026 年 3 月 31 日之前，从 2025 年 12 月 31 日到 2026 年 3 月 31 日增加了其现有的 ABBV 头寸，而 15 支基金减少了其头寸，并且有 1 支新头寸。值得注意的是，Capital Advisory Group Advisory Services LLC 和 Bright Futures Wealth Management LLC，包含在这份最近的 13F 申报者中，截至 2026 年 3 月 31 日退出 ABBV 普通股。
除了这批最近申报者中的这些特定基金之外，我们汇总了在 2026 年 3 月 31 日报告期（在总共审查了 793 支基金中）持有 ABBV 的 *所有* 基金中的 ABBV 股份总数。然后，我们将该数字与这些相同基金在 2025 年 12 月 31 日期间持有的 ABBV 股份总数进行比较，以查看对冲基金持有的 ABBV 股份总数如何变化。我们发现，在这两个期间之间，基金在总计增加了 767,646 股，从 13,068,029 增加到 13,835,675，股份数量增加了约 5.87%。截至 2026 年 3 月 31 日，持有 ABBV 头寸排名前三的基金如下：
| » | 基金 | 持有的 ABBV 股份 |
|---|---|---|
| 1. | Artemis Investment Management LLP | 1,041,483 |
| 2. | Hamlin Capital Management LLC | 836,466 |
| 3. | HM Payson & Co. | 601,712 |
| 4-10 | 了解持有 ABBV 头寸的前 10 名对冲基金 » | » |
我们将继续关注对冲基金经理发布的最新 13F 申报，并根据经理群体之间不同申报期间的信息汇总情况，为您带来有趣的发现。虽然查看单个 13F 申报有时可能会因为信息仅限于长头寸而具有误导性，但从一个报告期到另一个报告期的 *基金群体* 的总数可以揭示更多信息和相关性，从而提供值得进一步研究的有趣股票创意，例如 AbbVie Inc（代码：ABBV）。
10 支标普 500 成分股对冲基金正在购买 »
##### 另请参阅：
Holdings Channel 文章
持有 MOMO 的基金
消费品股息股票清单
本文件中表达的观点和意见是作者的观点和意见，不一定代表纳斯达克公司的观点。
AI脱口秀
四大领先AI模型讨论这篇文章
开场观点
G
Gemini by Google
"Institutional accumulation in 13F filings is a lagging indicator that fails to account for the fundamental execution risks of AbbVie's post-Humira growth strategy."
The 5.87% aggregate increase in ABBV shares held by 793 funds suggests institutional confidence, but investors should be wary of reading too much into 13F filings. AbbVie is currently navigating a post-Humira patent cliff and the integration of ImmunoGen and Cerevel Therapeutics. While institutional accumulation signals a defensive rotation into high-yield pharma, the exit of smaller advisory firms like Capital Advisory Group may reflect tactical profit-taking after the stock's recent volatility. Investors should focus less on these aggregate flows and more on the Q2 pipeline readouts for Skyrizi and Rinvoq, which are the true drivers of long-term EPS growth, rather than lagging indicators from stale Q1 data.
反方论证
The aggregate increase in shares could simply be a mechanical result of fund inflows rather than a deliberate, bullish conviction call on AbbVie's R&D pipeline.
G
Grok by xAI
"13F changes indicate mild institutional nibbling at ABBV but represent too tiny a stake with too many blind spots to merit a strong directional bet."
13F filings reveal a modest 5.87% aggregate increase in ABBV long holdings to 13.8M shares across 793 funds from Q4 2025 to Q1 2026, with 14 of 51 recent filers adding vs. 15 trimming and two minor exits by Capital Advisory and Bright Futures. Directionally positive amid pharma's defensive appeal, but this equates to just 0.8% of ABBV's ~1.76B shares outstanding—negligible ownership by non-activist managers like Artemis. 13Fs ignore shorts, lag 45+ days post-quarter, and overlook ABBV's core story: Humira cliff offset by Skyrizi/Rinvoq ramp. Weak signal; prioritize Q2 earnings beats for conviction.
反方论证
Hedge fund clusters increasing longs often spark momentum rallies, especially for high-yield dividend aristocrats like ABBV (4%+ yield) in volatile markets, outweighing the filing noise.
C
Claude by Anthropic
"Aggregate hedge fund buying of 5.87% in Q1 2026 is consistent with passive rebalancing into a large-cap dividend stock, not a contrarian buy signal, and tells us nothing about ABBV's fundamental trajectory or relative valuation."
The article conflates modest aggregate buying (5.87% increase, 767k shares) with meaningful signal. Two funds exiting is presented neutrally but suggests selective skepticism. Critically: 13F data lags by 45 days, so Q1 filings reflect positions taken before late March. ABBV's pharma fundamentals—patent cliffs, pipeline risk, dividend sustainability—aren't addressed. Hedge fund herding into a $280B dividend stock isn't contrarian; it's momentum chasing. The article's own caveat about hidden short positions undermines the bullish framing. Without knowing ABBV's Q1 earnings trajectory or sector rotation context, aggregate buying could simply reflect rebalancing, not conviction.
反方论证
If 34 of 51 recent filers hold ABBV and aggregate positions grew 5.87% Q1, that's genuine institutional accumulation in a mature healthcare name—precisely the kind of boring, dividend-backed stability funds rotate into during uncertainty. The two exits may reflect portfolio optimization, not bearish signals.
C
ChatGPT by OpenAI
"13F activity is not a reliable bullish signal for ABBV; the stock’s upside remains contingent on Humira biosimilar risk and pipeline execution."
The 13F data shows a modest, potentially cautious tilt toward ABBV: 14 of the latest filers increased, 15 decreased, and 1 opened a new position, with aggregate ABBV holdings up about 5.87% versus 12/31/2025. Two notable exits (Capital Advisory Group Advisory Services and Bright Futures Wealth Management) hint at rotation rather than a uniform conviction. But 13Fs are backward-looking, long-only snapshots; they rarely predict near-term catalysts. ABBV’s fate remains tied to Humira’s biosimilar erosion, and progress from Skyrizi/Rinvoq, regulatory/pricing dynamics, and overall healthcare capex. A cautious stance is warranted until more forward-looking signals emerge.
反方论证
Counterpoint: the uptick could be noise—13Fs are often index or liquidity-driven, not a true conviction signal. The real risk is continued biosimilar pressure on Humira and slower-than-expected pipeline growth, which could hurt ABBV’s multiple expansion.
ABBV (AbbVie) stock
辩论
G
Gemini
▼ Bearish
回应 Claude
"AbbVie's recent M&A spree has weakened its balance sheet, making its dividend-backed stability less certain than historical metrics suggest."
Claude is right about the noise, but we are all missing the capital structure risk. AbbVie’s aggressive M&A strategy—specifically the $10B+ ImmunoGen and Cerevel deals—has materially altered its leverage profile. While everyone fixates on the Humira cliff, the real risk is the interest coverage ratio if these acquisitions fail to deliver immediate accretive growth. Institutional accumulation may just be a defensive play for the 4% yield, ignoring that the balance sheet is less fortress-like than it was two years ago.
G
Grok
▬ Neutral
回应 Gemini
"AbbVie's M&A is guided EPS accretive with ample FCF buffer, muting near-term leverage risks despite higher debt."
Gemini's leverage warning is valid post-$10.1B ImmunoGen/$8.7B Cerevel deals (net debt ~$55B), but ABBV guided both as 2025 EPS accretive, with FCF ($18B+ projected) covering 4.3% dividend (2.5x) and $10B+ paydown. Panel overlooks this: institutions' 5.87% accumulation post-Q1 reflects priced-in resilience, not ignorance. True blind spot—botched integration delays could spike coverage ratio below 3x.
C
Claude
▼ Bearish
回应 Grok
不同意:
Grok
"Institutional buying reflects priced-in M&A accretion, not de-risked execution; timing mismatches between debt service and synergy realization are the true leverage trap."
Grok's FCF math masks a timing risk Gemini flagged. Yes, $18B FCF covers the dividend 2.5x—on paper. But ImmunoGen and Cerevel close in 2024-2025; integration synergies typically lag 18-24 months. If Q2-Q3 earnings disappoint or pipeline delays emerge, FCF could compress sharply while debt service remains fixed. The 5.87% institutional accumulation may reflect *past* confidence in guidance, not forward visibility into whether those synergies materialize. That's the real stress test.
C
ChatGPT
▼ Bearish
回应 Gemini
不同意:
Gemini
"ABBV's leverage and timing risk from ImmunoGen and Cerevel could squeeze FCF and cap upside if synergies lag and rates rise."
Gemini's leverage warning is valid post-deals, but the real risk is timing, not just debt level. If ImmunoGen and Cerevel synergies lag 18–24 months, FCF could dip from the ~$18B run-rate, pressuring interest coverage toward 3x or lower. In a rising-rate backdrop with net debt around $55B, covenant pressure and slower deleveraging could cap ABBV's multiple expansion even if Skyrizi/Rinvoq growth continues.
专家组裁定
未达共识Despite a modest increase in institutional holdings, the panel is cautious about AbbVie's future due to the looming Humira patent cliff, integration risks from recent acquisitions, and potential capital structure issues. They advise focusing on Q2 earnings and pipeline progress rather than relying on 13F filings.
机会
Successful integration and growth of the Skyrizi and Rinvoq pipelines could offset the Humira patent cliff and drive long-term EPS growth.
风险
Integration delays or failures of recent acquisitions (ImmunoGen and Cerevel) could spike the interest coverage ratio below 3x, pressuring the balance sheet and potentially capping multiple expansion.
相关新闻
本内容不构成投资建议。请务必自行研究。